1. | | Recruiting | Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects with Anemia of Cancer Condition: Anemia |
2. | | Recruiting | A Study of Darbepoetin Alfa in Anemic Subjects with Low Risk Myelodysplastic Syndrome Condition: Myelodysplastic Syndromes |
3. | | Recruiting | Study of TRM-1 (TRAIL-R1 monoclonal antibody) in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Condition: Lymphoma, Non-Hodgkin |
4. | | Recruiting | Tipifarnib versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Conditions: Myeloid Leukemia; Acute Disease |
5. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma |
6. | | Recruiting | Fludarabine, Low-Dose Total-Body Irradiation, Donor Stem Cell Transplantation, and Immunosuppression Therapy in Treating Patients Who Have Fanconi’s Anemia Conditions: Fanconi's Anemia; adult acute myeloid leukemia; childhood acute myeloid leukemia; Graft Versus Host Disease; Myelodysplastic Syndromes |
7. | | Recruiting | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma Conditions: recurrent adult Hodgkin's lymphoma; recurrent adult Burkitt's lymphoma; post-transplant lymphoproliferative disorder; ... |
8. | | Recruiting | Darbepoetin alfa in Treating Anemic Patients With Myelodysplastic Syndromes Conditions: Anemia; Fatigue; Myelodysplastic Syndromes |
9. | | Recruiting | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Conditions: adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); ... |
10. | | Recruiting | Anti-Thymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplantation for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Graft Versus Host Disease; secondary acute myeloid leukemia |
11. | | Recruiting | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
12. | | Recruiting | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; Myelodysplastic Syndromes |
13. | | Recruiting | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
14. | | Recruiting | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Conditions: de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; ... |
15. | | Recruiting | Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) with Hemophilia B Condition: Hemophilia B |
16. | | Recruiting | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Condition: Multiple Myeloma |
17. | | Recruiting | ReFacto® in Subjects with Hemophilia A Undergoing Major Surgery Condition: Hemophilia A |
18. | | Recruiting | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma Condition: Lymphoma, Follicular |
19. | | Recruiting | Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU) Condition: Anemia |
20. | | Recruiting | A Longitudinal Study of Familial Hyperosinophilia (FE): Natural History and Markers of Disease Progression Condition: Eosinophilia |
21. | | Recruiting | Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer Conditions: Anemia; Cancer |
22. | | Recruiting | Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients with Follicular Lymphoma Condition: Non-Hodgkins Lymphoma |
23. | | Recruiting | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) Condition: Multiple Myeloma |
24. | | Recruiting | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma Conditions: Cutaneous T-Cell Lymphoma; Sezary Syndrome; Mycosis Fungoides |
25. | | Recruiting | Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
26. | | Recruiting | CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome |
27. | | Recruiting | Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction Conditions: adult non-Hodgkin's lymphoma; adult primary liver cancer; adult solid tumor |
28. | | Not yet recruiting | Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma Conditions: long-term effects secondary to cancer therapy in children; stage I childhood Hodgkin's lymphoma; stage II childhood Hodgkin's lymphoma; ... |
29. | | Recruiting | Epoetin alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy Conditions: adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm |
30. | | Recruiting | Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Condition: recurrent adult Hodgkin's lymphoma |
31. | | Recruiting | Chemotherapy for Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma Conditions: Solid Malignancies; Non-Hodgkin's Lymphoma |
32. | | Not yet recruiting | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma Condition: Multiple Myeloma |
33. | | Recruiting | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma Conditions: B-Cell Lymphoma; T-Cell Lymphoma |
34. | | Recruiting | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma Condition: Non-Hodgkin's Lymphoma |
35. | | Recruiting | Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Condition: Lymphoma |
36. | | Recruiting | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome |
37. | | Recruiting | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant Condition: Multiple Myeloma |
38. | | Recruiting | Cilengitide in Treating Patients With Acute Myeloid Leukemia Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia |
39. | | Recruiting | Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage II, Stage III, or Stage IV Relapsed or Refractory Non-Hodgkin's Lymphoma Conditions: adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma |
40. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas Conditions: adult solid tumor; Leukemia; Lymphoma |
41. | | Recruiting | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Conditions: refractory chronic lymphocytic leukemia; noncontiguous stage II small lymphocytic lymphoma; recurrent small lymphocytic lymphoma; ... |
42. | | Recruiting | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
43. | | Recruiting | Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia |
44. | | Recruiting | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who are Undergoing Donor Stem Cell Transplantation Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Graft Versus Host Disease; hematopoietic and lymphoid cancer |
45. | | Recruiting | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplantation for Hematologic Cancer Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Graft Versus Host Disease; hematopoietic and lymphoid cancer |
46. | | Not yet recruiting | FR901228 in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Acute Myeloid Leukemia Conditions: adult acute myeloid leukemia; refractory chronic lymphocytic leukemia; Small Lymphocytic Lymphoma |
47. | | Not yet recruiting | Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma Conditions: stage I adult diffuse large cell lymphoma; stage II adult diffuse large cell lymphoma |
48. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
49. | | Recruiting | Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
50. | | Recruiting | A Study to Assess SOM230 in Patients with Pituitary Cushing’s Disease Condition: Cushing's Syndrome |